ArticleActa neuropathologica communications2026
Microvascular pathology in the spinal cord of severe spinal muscular atrophy patients.
Article in Acta neuropathologica communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- MyomiR Networks in Spinal Muscular Atrophy: Associations With Clinical Severity and Treatment Response.Molecular neurobiology · 2026Article
- Thrombosis in Neuromuscular Medicine: Current Evidence, Unmet Needs, and Future Directions.Journal of clinical medicine · 2026Review
- When barriers fail: the role of endothelial dysfunction in rare pediatric neuromuscular diseases.Frontiers in medicine · 2026Review
Corrections and comments
- Update of
Authors and funding
6 authors.
Funding
Abstract
Severe spinal muscular atrophy (SMA) is a life-limiting neurodegenerative disease of infancy and early childhood, caused by reduced expression of the ubiquitous survival motor neuron protein (SMN). While current therapies aim to increase SMN levels and preserve motor neurons, significant deficits remain in treated patients and non-neuronal manifestations of SMN deficiency are underexplored. Vascular abnormalities including intrinsic endothelial cell dysfunction, altered vessel morphology, and altered vascular distribution have been reported in preclinical SMA models. Here, we characterised vascular architecture and blood-spinal cord barrier (BSCB) morphology and integrity in post-mortem spinal cord samples from severe SMA patients compared with unaffected controls. Von Willebrand Factor (vWF), a marker of endothelial cell health, was reduced within individual vascular endothelial cells, and associated with ultrastructural endothelial cell oedema, vacuolisation and compromised endothelial integrity. Ultrastructural damage extended to other components of the BSCB as evidenced by extravascular leakage of fibrinogen into the neural parenchyma and microglial activation consistent with a neuroinflammatory environment. Together, these findings suggest that vascular defects with associated dysfunction of the BSCB are present in the spinal cord of infants with severe SMA. This work adds to a growing body of evidence linking microvascular dysfunction to neurodegeneration in human neurodegenerative diseases. Further studies are warranted to define the contribution of vascular dysfunction to SMA pathogenesis and to assess whether current therapies adequately address this aspect of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.